Short Interest in Viracta Therapeutics, Inc. (NASDAQ:VIRX) Rises By 89.9%

by · The Markets Daily

Viracta Therapeutics, Inc. (NASDAQ:VIRX – Get Free Report) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 3,000,000 shares, an increase of 89.9% from the November 30th total of 1,580,000 shares. Based on an average trading volume of 2,140,000 shares, the short-interest ratio is currently 1.4 days. Currently, 10.7% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada decreased their price target on shares of Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th.

Read Our Latest Research Report on Viracta Therapeutics

Institutional Investors Weigh In On Viracta Therapeutics

An institutional investor recently bought a new position in Viracta Therapeutics stock. Stonepine Capital Management LLC acquired a new stake in Viracta Therapeutics, Inc. (NASDAQ:VIRX – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned 1.27% of Viracta Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Viracta Therapeutics Stock Down 5.2 %

Shares of VIRX stock opened at $0.24 on Friday. The firm has a market cap of $9.42 million, a price-to-earnings ratio of -0.22 and a beta of 0.67. Viracta Therapeutics has a 12 month low of $0.13 and a 12 month high of $1.31. The stock has a 50-day moving average price of $0.19 and a 200 day moving average price of $0.32.

Viracta Therapeutics Company Profile

(Get Free Report)

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.

Featured Stories